Across TCGA pan-cancer cohorts, NDUFA12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NDUFA12 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NDUFA12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NDUFA12 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where NDUFA12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	1.000	0.809	.012	21	view →
PDAC	DFS	Tertile	All	0.611	0.363	.009	13	view →
HNSC	DFS	Median	II,III,IV	0.907	0.980	.025	3	view →
LUAD	OS	Quartile	III,IV	0.300	0.795	.033	3	view →
LSCC	DFS	Median	II,III,IV	0.836	0.999	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: NDUFA12 tumor-vs-normal RNA expression · all NDUFA12 data types